Sign In
Buy CLNN
$5.76
-0.110 (-1.87%)
At Close: Jun 03, 2026
Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2
01:03am, Friday, 23'rd Jan 2026
Clene (NASDAQ: CLNN) executives told investors the clinical-stage biopharmaceutical company has secured an in-person meeting with the U.S. Food and Drug Administration (FDA) later this quarter as it c
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $100,459.52 in Stock
04:44am, Monday, 19'th Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 19,621 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The stock was sold a
Clene (NASDAQ:CLNN) Major Shareholder Sells $64,071.30 in Stock
04:44am, Monday, 19'th Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 12,563 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at
Chidozie Ugwumba Sells 26,105 Shares of Clene (NASDAQ:CLNN) Stock
05:40am, Sunday, 18'th Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 26,105 shares of Clene stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of
Clene to Present at the Emerging Growth Conference
08:30am, Friday, 16'th Jan 2026
SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar
David Matlin Buys 33,333 Shares of Clene (NASDAQ:CLNN) Stock
04:44am, Thursday, 15'th Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) Director David Matlin acquired 33,333 shares of the business's stock in a transaction on Tuesday, January 13th. The stock was acquired at an average price o
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
08:30am, Monday, 12'th Jan 2026
SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a
Clene Announces Registered Direct Offering of Over $28 Million
08:30am, Friday, 09'th Jan 2026
Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $24,952.14 in Stock
05:12am, Saturday, 03'rd Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,138 shares of the stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $
Chidozie Ugwumba Sells 8,096 Shares of Clene (NASDAQ:CLNN) Stock
05:10am, Friday, 02'nd Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 8,096 shares of the business's stock in a transaction that occurred on Monday, December 29th. The stock was sold at
Clene (NASDAQ:CLNN) Major Shareholder Sells $42,830.37 in Stock
05:10am, Friday, 02'nd Jan 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,831 shares of Clene stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of
Clene Inc. (NASDAQ:CLNN) Given Consensus Rating of “Moderate Buy” by Analysts
05:45am, Monday, 29'th Dec 2025
Clene Inc. (NASDAQ: CLNN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One equities researc
Clene (NASDAQ:CLNN) Major Shareholder Sells $444,695.22 in Stock
06:06am, Sunday, 21'st Dec 2025
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 56,577 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sol
Clene to Present at the Emerging Growth Conference
08:30am, Tuesday, 09'th Dec 2025
SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
08:10am, Tuesday, 09'th Dec 2025
MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The
